“

Per policy, we are not able to comment on whether or not we will take any action regarding emergency use authorization for convalescent plasma and will render a decision at the appropriate time, of note, the safe use of convalescent plasma remains available to patients through several pathways, including clinical trials, a national expanded access protocol, or through a single patient emergency investigational new drug request.